Oculis Holding Ag OCS

$7.90 -0.19 (-2.35%)

Valuation

Market cap
458,074,000
Revenue TTM
$1,450,000
Net income TTM
$-119,440,000
PE ratio
0.00
Forward PE
—
Profit margin
-8,237.24%
Debt to equity
0.00

Trading

Volume
294,700
Avg volume
254,026
Day's range
$7.82 – $8.07
Shares out
57,984,000
Stochastic %K
66%
Beta
0.62
Analysts
Strong Sell
Price target
$37.90

Price

Company profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2...

Show more

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.

Industry
Biotechnology
Sector
Healthcare
Phone
41 41 711 3960
Website
https://oculis.com
Address
Bahnhofstrasse 20, Zug, Switzerland

Latest news

Stocktwits

caronte Oct 23, 6:17 PM
$OCS let's keep in mind this ticker value is 30-40$
0 replies
Merlintrader Oct 22, 8:03 PM
$OCS Latest company news, Oct 22, 2026: new ACUITY biomarker data in acute optic neuritis: neurofilament light stayed stable through month 6 on privosegtor, and GFAP stayed below baseline on privosegtor while it ran above baseline on placebo. The company sees further support for neuroprotection; no numerical values were given. Full hub (privosegtor, pipeline, cash): https://www.merlintrader.com/oculis-holding-ag-stock-hub/ Not investment advice.
0 replies
Merlintrader Oct 19, 3:59 PM
Latest company news, October 19, 2026: Oculis completed randomization in PREDICT-1 of licaminlimab in dry eye disease (176 patients). Topline still expected around year-end 2026. An operational milestone, not data. Oculis Holding AG $OCS: Pipeline, Cash And Clinical Tests Deeper dive in our hub. Not investment advice.
0 replies
caronte Oct 14, 5:24 PM
$OCS this should vale 40$
0 replies
caronte Oct 14, 2:29 PM
$OCS
0 replies
caronte Oct 14, 2:45 AM
$OCS
0 replies
caronte Oct 13, 7:10 PM
$OCS
0 replies
caronte Oct 13, 6:29 PM
$OCS
0 replies